Literature DB >> 17652880

Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis.

Junichi Hoshino1, Yoshifumi Ubara, Shigeko Hara, Yoko Sogawa, Tatsuya Suwabe, Yasushi Higa, Shohei Nakanishi, Naoki Sawa, Hideyuki Katori, Fumi Takemoto, Yo Fujimoto, Eiichi Ohta, Kanetoshi Ohara, Kenmei Takaichi.   

Abstract

BACKGROUND: Severe arteriosclerosis obliterans (ASO) can be intractable, especially in diabetic patients on hemodialysis (HD). Recently, the transplantation of autologous peripheral blood mononuclear cells (PBMNCs) has been reported to have beneficial effects, but the long-term effects and impact on quality of life (QOL) have not been studied. METHODS AND
RESULTS: Autologous PBMNCs were transplanted into 7 diabetic patients on HD who had severe ASO (5 cases with Fontaine IV and 2 with Fontaine III) after administration of 5 microg/kg granulocyte colony stimulating factor; QOL and degree of ischemia was assessed by measuring skin temperature, skin perfusion pressure (SPP), ankle-brachial index (ABI), and ulcer size, and from angiographic findings. At 4 weeks after the procedure, skin temperature was significantly improved, and SPP and ABI also were increased. These beneficial effects persisted for up to 24 weeks. Angiographic findings and ulcer size improved in 3 of 7 and 3 of 4 patients, respectively. SF-36v2 analysis revealed significant improvements in pain scores. No serious complications were detected.
CONCLUSION: Transplantation of PBMNCs resulted in improvement in pain and leg ischemia for over 6 months without serious complications. This therapy is safe and effective for severe ASO in diabetic patients on HD.

Entities:  

Mesh:

Year:  2007        PMID: 17652880     DOI: 10.1253/circj.71.1193

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

1.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.

Authors:  S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29

Review 2.  PBMNCs Treatment in Critical Limb Ischemia and Candidate Biomarkers of Efficacy.

Authors:  Matilde Zamboni; Massimo Pedriali; Luca Ferretto; Sabrina Scian; Francesca Ghirardini; Riccardo Bozza; Romeo Martini; Sandro Irsara
Journal:  Diagnostics (Basel)       Date:  2022-05-04

Review 3.  Clinical Application of Endothelial Progenitor Cell: Are We Ready?

Authors:  Chao-Hung Wang; Po-Hsun Huang; Jaw-Wen Chen; Shing-Jong Lin; Ming-Feng Lee; Ning-I Yang; Wen-Jin Cherng
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

4.  Early and Long-term Effects of the Autologous Peripheral Stem Cell Implantation for Critical Limb Ischemia.

Authors:  Takahiro Nishida; Yasutaka Ueno; Takashi Kimura; Ryousuke Ogawa; Kunihiko Joo; Ryuji Tominaga
Journal:  Ann Vasc Dis       Date:  2011-11-30

Review 5.  Emerging hurdles in stem cell therapy for peripheral vascular disease.

Authors:  Xabier L Aranguren; Catherine M Verfaillie; Aernout Luttun
Journal:  J Mol Med (Berl)       Date:  2008-08-19       Impact factor: 4.599

6.  A Five-Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis-Induced No-Option Critical Limb Ischemia.

Authors:  Yuan Fang; Zheng Wei; Bin Chen; Tianyue Pan; Shiyang Gu; Peng Liu; Daqiao Guo; Xin Xu; Junhao Jiang; Jue Yang; Zhenyu Shi; Ting Zhu; Yun Shi; Yifan Liu; Zhihui Dong; Weiguo Fu
Journal:  Stem Cells Transl Med       Date:  2018-04-30       Impact factor: 6.940

7.  Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia.

Authors:  Xiaolang Jiang; Hao Liu; Tianyue Pan; Shiyang Gu; Yuan Fang; Zheng Wei; Gang Fang; Bin Chen; Junhao Jiang; Yun Shi; Peng Liu; Weiguo Fu; Zhihui Dong
Journal:  Front Cardiovasc Med       Date:  2021-12-06

Review 8.  Introduction to clinical research based on modern epidemiology.

Authors:  Junichi Hoshino
Journal:  Clin Exp Nephrol       Date:  2020-03-24       Impact factor: 2.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.